Results 241 to 250 of about 279,221 (285)

Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth. [PDF]

Cell Commun Signal
Smith JP, Mohit M, Kenner J, Nathan A, Drda J, Gay MD, Cao H, Chen W, Gomeiz A, Baldelli E, Dou W, Fang HB, Shivapurkar N, Davis J, Wei Q, Akhrif A, Pierobon M.   +16 more
europepmc   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy. [PDF]

Cell Oncol (Dordr)
Nasir Kansestani A, Zare ME, Zhang J.
europepmc   +1 more source

Unveiling the Role of CCL3: A Driver of CIPN in Colon Cancer Patients? [PDF]

Biomedicines
Luzac I, Regalado CR, Balogh M.
europepmc   +1 more source

CCR2/CXCR6 enhances tumor infiltration and antitumor efficacy of MSLN CAR-T cells. [PDF]

Cell Mol Life Sci
Zhang Y, Zhao L, Liu J, Yang X, Chen T, Chen Z, Li W, Hu Z, Pan F, Chen J, He L, Guo Z.   +11 more
europepmc   +1 more source

Neutrophil membrane-coated nanoparticles for targeted therapy. [PDF]

Discov Nano
Ma J, Pei H, Wang F, Shen D.
europepmc   +1 more source

CAR-NK Engineering to Overcome TME Barriers. [PDF]

Cells
Islam F, Pupovac A, Boyd RL, Trounson AO.   +3 more
europepmc   +1 more source